Cempra Pharmaceuticals gave poster presentations last week on its novel antibiotic CEM-101, a next-generation macrolide, and CEM-102 (TAKSTA), the company's proprietary front-loading oral dosing regimen of sodium fusidate. The presentations were made at the 20th European Congress of Clinical Microbiology and Infectious Disease in Vienna, Austria.
CEM-101 has shown a broad spectrum of activity and high potency against respiratory and other serious pathogens in both in vitro and in vivo studies. The results from the first Phase I dose escalation study demonstrated that doses of CEM-101 from 200 to 600 mg were safe and well tolerated in healthy subjects and that the compound's pharmacokinetic profile is supportive of once-daily dosing.
Despite being available for over 40 years in Europe, sodium sodium fusidate (TAKSTA, CEM-102) demonstrated sustained activity against S. aureus including methicillin-resistant strains indicating that the compound is not highly susceptible to resistance development.
- read this Cempra release for more